Meeting
2022 ASCO Genitourinary Cancers Symposium
Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients.
Authors
Thomas Gerald
University of Texas Southwestern Medical Center, Dallas, TX
Thomas Gerald , Vitaly Margulis , Xiaosong Meng , Suzanne Cole , Qian Qin , Greg Call , Elizabeth Mauer , Yair Lotan , Solomon L. Woldu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 525)
DOI
10.1200/JCO.2022.40.6_suppl.525
Abstract #
525
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran
Poster
2023 ASCO Annual Meeting
Spectrum of germline pathogenic variants among patients with cancer in Mexico.
First Author: Jose Luis Rodriguez Olivares
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon